Clinical Trial: GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer

U.S., April 29 -- ClinicalTrials.gov registry received information related to the study (NCT07554859) titled 'GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer' on April 21.

Brief Summary: This study is a multicenter, open-label, randomized clinical trial aimed at exploring the efficacy and safety of three treatment regimens for treatment-naive advanced NSCLC patients with KRAS G12D mutation: GFH375 monotherapy (Cohort 1), GFH375 combined with cetuximab (Cohort 2), and GFH375 combined with pemetrexed (Cohort 3).Every cohort will recruit 30 participants.

Study Start Date: May 20

Study Type: INTERVENTIONAL

Condition: NSCLC (Advanced Non-small Cell Lung Cancer)

Int...